DNA Script company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

dnascript.com

Executives

4

Board of Directors

4

DNA Script Board of Directors

4 Board of directors

DNA Script has 4 board of directors, including Joško Bobanović.

Name

Firm

Work History

Other Seats

Joško Bobanović

Joško Bobanović joined Sofinnova Partners in 2010 as a Partner dedicated to activities in industrial biotech. He focuses on early stage deals in Europe and North America with applications in chemicals, agriculture, food, feed and synthetic biology. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital in Montreal, Canada. Prior to his venture capital career he created an internet startup and a software company. Joško holds a BSc. in physics from University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.

DNA Script

Nicholas Naclerio

Nick is Founding Partner of Illumina Ventures, an early stage venture capital firm strategically aligned with Illumina. From 2010 to April 2016, Nick served as Illumina’s Senior Vice President of Corporate and Venture Development. In April 2016, Nick left to found Illumina Ventures, where he manages investments and participates on company boards. From 2014 to 2015, Nick also served as the founding General Manager of Illumina’s Enterprise Informatics Business Unit. Before joining Illumina, Nick co-founded and was the Executive Chairman of Quanterix, an emerging diagnostics company based on a novel single-molecule detection platform. Previously, he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. He was also the founding Vice President and General Manager of Motorola Life Sciences. He also held leadership roles at Zyomyx Inc., Motorola Ventures, the Defense Advanced Research Projects Agency (DARPA) and the U.S. Air Force. Additionally, Nick has served on a number of corporate and institutional boards, including Twist Bioscience, Boreal Genomics, the SNP Consortium, Genometrix, Clinical Microsensors, Orchid Bioscience and SEMATECH. Nick received a BS in Electrical Engineering and Computer Science from Duke University, a Winston Churchill Fellowship in Materials Science to Cambridge University and a PhD in Electrical Engineering from the University of Maryland.

DNA Script

Philippe Peltier

DNA Script

Thomas Ybert

DNA Script

Name

Joško Bobanović

Nicholas Naclerio

Philippe Peltier

Thomas Ybert

Firm

Work History

Joško Bobanović joined Sofinnova Partners in 2010 as a Partner dedicated to activities in industrial biotech. He focuses on early stage deals in Europe and North America with applications in chemicals, agriculture, food, feed and synthetic biology. Prior to joining Sofinnova he spent eight years in venture capital with iNovia Capital in Montreal, Canada. Prior to his venture capital career he created an internet startup and a software company. Joško holds a BSc. in physics from University of Zagreb, a PhD in physical oceanography from Dalhousie University and an MBA in finance and marketing from McGill University.

Nick is Founding Partner of Illumina Ventures, an early stage venture capital firm strategically aligned with Illumina. From 2010 to April 2016, Nick served as Illumina’s Senior Vice President of Corporate and Venture Development. In April 2016, Nick left to found Illumina Ventures, where he manages investments and participates on company boards. From 2014 to 2015, Nick also served as the founding General Manager of Illumina’s Enterprise Informatics Business Unit. Before joining Illumina, Nick co-founded and was the Executive Chairman of Quanterix, an emerging diagnostics company based on a novel single-molecule detection platform. Previously, he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. He was also the founding Vice President and General Manager of Motorola Life Sciences. He also held leadership roles at Zyomyx Inc., Motorola Ventures, the Defense Advanced Research Projects Agency (DARPA) and the U.S. Air Force. Additionally, Nick has served on a number of corporate and institutional boards, including Twist Bioscience, Boreal Genomics, the SNP Consortium, Genometrix, Clinical Microsensors, Orchid Bioscience and SEMATECH. Nick received a BS in Electrical Engineering and Computer Science from Duke University, a Winston Churchill Fellowship in Materials Science to Cambridge University and a PhD in Electrical Engineering from the University of Maryland.

Other Seats

DNA Script

DNA Script

DNA Script

DNA Script

DNA Script Management Team

4 Team Members

DNA Script has 4 executives. DNA Script's current Founder, Chief Operating Officer is Sylvain Gariel.

Name

Work History

Title

Status

Sylvain Gariel

Founder, Chief Operating Officer

Current

Xavier Godron

Founder, Chief Technology Officer

Current

Thomas Ybert

Amyris, TotalEnergies, and Sanofi-Aventis

Founder, Chief Executive Officer

Current

Philippe Lyko

Chief Financial Officer

Current

Name

Sylvain Gariel

Xavier Godron

Thomas Ybert

Philippe Lyko

Work History

Amyris, TotalEnergies, and Sanofi-Aventis

Title

Founder, Chief Operating Officer

Founder, Chief Technology Officer

Founder, Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Current

Current

You May Also Like

Kilobaser Logo
Kilobaser

KioBaser is building what it dubs "Nespresso machine of DNA synthesis". The machine creates DNA primers, a short single strand of RNA or DNA (generally about 18-22 bases) that serves as a starting point for DNA synthesis.

Evonetix Logo
Evonetix

Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with application across industries including healthcare, pharma, biotech, food and agriculture and data storage.

Molecular Assemblies Logo
Molecular Assemblies

Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage.

H
Helixworks Technologies

Helixworks Technologies is a biotechnology company specializing in DNA synthesis.

I
Iridia

Iridia is developing a DNA-based data storage solution. By combining DNA polymer synthesis technology, electronic nano-switches and semiconductor fabrication technologies, Iridia is developing a highly-parallel format to enable an array of nanomodules with the potential to store data at exceptionally high density.

S
Synthomics

Developer of instrumentation for gene synthesis analysis. The company develops a DNA and RNA synthesizer for molecular biology research purposes. The platform aims to deliver less expensive, higher quality, reduced turn-around-time oligonucleotide synthesis solutions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.